Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.

Hamiditabar M, Ali M, Roys J, Wolin EM, OʼDorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES.

Clin Nucl Med. 2017 Jun;42(6):436-443. doi: 10.1097/RLU.0000000000001629.

PMID:
28263217
2.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators..

N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.

PMID:
28076709
3.

Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.

Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, Mintun MA, Pontecorvo MJ; 18F-AV-45-A17 Study Group..

Dement Geriatr Cogn Disord. 2016;41(1-2):80-92. doi: 10.1159/000441139. Epub 2016 Jan 8.

PMID:
26745445
4.

Radiosynthesis of clinical doses of ⁶⁸Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based ⁶⁸Ge/⁶⁸Ga generators.

Tworowska I, Ranganathan D, Thamake S, Delpassand E, Mojtahedi A, Schultz MK, Zhernosekov K, Marx S.

Nucl Med Biol. 2016 Jan;43(1):19-26. doi: 10.1016/j.nucmedbio.2015.08.004. Epub 2015 Sep 1.

PMID:
26702783
5.

Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using (68)Ga-DOTATATE PET/CT.

Mojtahedi A, Alavi A, Thamake S, Amerinia R, Ranganathan D, Tworowska I, Delpassand ES.

Am J Nucl Med Mol Imaging. 2014 Dec 15;5(1):65-71. eCollection 2015.

6.

The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES.

Am J Nucl Med Mol Imaging. 2014 Aug 15;4(5):426-34. eCollection 2014. Review.

7.

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A.

Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113.

PMID:
24632546
8.

Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.

Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA; 45-A17 Study Group..

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):4-15. doi: 10.1097/WAD.0b013e318279d02a.

PMID:
23203162
9.

Pictorial review of SPECT/CT imaging applications in clinical nuclear medicine.

Bhargava P, He G, Samarghandi A, Delpassand ES.

Am J Nucl Med Mol Imaging. 2012;2(2):221-31. Epub 2012 Mar 28.

10.

Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.

Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espenan GD, Sharif R, Mackenzie S, Kosari K, Barakat O, Naqvi S, Seng JE, Anthony L.

Theranostics. 2012;2(5):472-80. doi: 10.7150/thno.3739. Epub 2012 May 11.

11.

Peptide receptor radionuclide therapy in the United States.

Bhargava P, Delpassand ES.

J Nucl Med. 2012 May;53(5):839-40; author reply 840. doi: 10.2967/jnumed.112.104257. Epub 2012 Mar 15. No abstract available.

12.

Detecting global and local hippocampal shape changes in Alzheimer's disease using statistical shape models.

Shen KK, Fripp J, Mériaudeau F, Chételat G, Salvado O, Bourgeat P; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage. 2012 Feb 1;59(3):2155-66. doi: 10.1016/j.neuroimage.2011.10.014. Epub 2011 Oct 14.

PMID:
22037419
13.

Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data.

Cho Y, Seong JK, Jeong Y, Shin SY; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage. 2012 Feb 1;59(3):2217-30. doi: 10.1016/j.neuroimage.2011.09.085. Epub 2011 Oct 8.

PMID:
22008371
14.

BEaST: brain extraction based on nonlocal segmentation technique.

Eskildsen SF, Coupé P, Fonov V, Manjón JV, Leung KK, Guizard N, Wassef SN, Østergaard LR, Collins DL; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage. 2012 Feb 1;59(3):2362-73. doi: 10.1016/j.neuroimage.2011.09.012. Epub 2011 Sep 16.

15.

Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis.

McEvoy LK, Holland D, Hagler DJ Jr, Fennema-Notestine C, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative..

Radiology. 2011 Jun;259(3):834-43. doi: 10.1148/radiol.11101975. Epub 2011 Apr 6.

16.

Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.

Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW; Alzheimer's Disease NeuroImaging Initiative..

Brain. 2011 Apr;134(Pt 4):1077-88. doi: 10.1093/brain/awr044. Epub 2011 Mar 22.

17.

Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.

Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative., Goate AM.

PLoS One. 2011 Feb 9;6(2):e15918. doi: 10.1371/journal.pone.0015918.

18.

Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.

Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C; Alzheimer's Disease Neuroimaging Initiative..

Arch Neurol. 2010 Nov;67(11):1370-8. doi: 10.1001/archneurol.2010.284.

19.

Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors.

Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, Espenan G, Moore WH, Woltering E, Anthony L.

Cancer Biother Radiopharm. 2008 Jun;23(3):292-300. doi: 10.1089/cbr.2007.0448.

PMID:
18593362
20.

166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.

Breitz HB, Wendt RE 3rd, Stabin MS, Shen S, Erwin WD, Rajendran JG, Eary JF, Durack L, Delpassand E, Martin W, Meredith RF.

J Nucl Med. 2006 Mar;47(3):534-42.

Supplemental Content

Loading ...
Support Center